WINTON GROUP Ltd Has $1.45 Million Stock Holdings in Krystal Biotech, Inc. $KRYS

WINTON GROUP Ltd decreased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 28.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,874 shares of the company’s stock after selling 2,338 shares during the period. WINTON GROUP Ltd’s holdings in Krystal Biotech were worth $1,448,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of KRYS. Bessemer Group Inc. lifted its position in Krystal Biotech by 106.9% during the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after acquiring an additional 77 shares during the last quarter. Sound Income Strategies LLC grew its position in shares of Krystal Biotech by 1,270.0% in the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after purchasing an additional 127 shares during the last quarter. Danske Bank A S bought a new position in shares of Krystal Biotech during the third quarter worth approximately $35,000. Global Retirement Partners LLC lifted its holdings in Krystal Biotech by 788.9% during the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after purchasing an additional 142 shares during the last quarter. Finally, MAI Capital Management lifted its holdings in Krystal Biotech by 79.7% during the 3rd quarter. MAI Capital Management now owns 284 shares of the company’s stock worth $50,000 after purchasing an additional 126 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on KRYS shares. Citigroup upped their price objective on Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Weiss Ratings raised Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, April 9th. Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. HC Wainwright restated a “buy” rating and issued a $310.00 price target on shares of Krystal Biotech in a research note on Monday, June 1st. Finally, Evercore reaffirmed an “outperform” rating and set a $300.00 price target on shares of Krystal Biotech in a research report on Tuesday, May 5th. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $324.11.

Krystal Biotech Trading Up 0.3%

Shares of Krystal Biotech stock opened at $301.76 on Tuesday. The company has a 50 day moving average of $283.40 and a 200-day moving average of $265.26. Krystal Biotech, Inc. has a 1-year low of $127.99 and a 1-year high of $319.48. The company has a market cap of $8.90 billion, a PE ratio of 40.34 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The business had revenue of $116.36 million for the quarter, compared to analysts’ expectations of $112.11 million. Research analysts forecast that Krystal Biotech, Inc. will post 7.83 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total value of $193,903.26. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.